QYJD Compound Preparation Promotes Rapid Postoperative Recovery in Early-stage NSCLC Patients by Regulating Tissue Microecology: a Prospective, Randomized Controlled, Open-label, Phase I Clinical Study With Predefined Future Exploration

QYJD compound preparation has the efficacy of clearing heat and removing toxins, dispelling blood stasis and relieving pain, etc. investigators aimed to explore the effect of expelling blood stasis and removing toxins compound preparation on the microecological changes of lungs of patients with early stage non-small cell lung cancer (NSCLC) by using metagenomics next-generation sequencing (mNGS) technology to carry out a prospective phase I clinical study. The aim of the study was to investigate the effect of the expelling stasis and detoxifying compound preparation on the microecology of lungs of patients with early-stage non-small cell lung cancer (NSCLC), and to conduct a prospective phase I clinical study to provide new ideas for promoting the postoperative rehabilitation of early-stage NSCLC.

1. participants screened for eligibility should sign the appropriate Informed Consent Form (ICF) prior to completing any study procedures.
2. The investigator will review symptoms, risk factors, and other non-invasive inclusion and exclusion criteria.

Eligibility Criteria:
Study Population Patients diagnosed with early-stage non-small cell lung cancer in accordance with the Primary Lung Cancer Diagnosis and Treatment Guidelines (2022 Edition) issued by the National Health and Health Commission and the TNM staging criteria of the 8th edition of the International Association for the Study of Lung Cancer (IASLC).

Inclusion criteria:

1. Patients with (a) no contraindications to surgery, early stage NSCLC diagnosed by postoperative pathology, and clinical stage I-IIIA; (b) aged 18-80 years old, with KPS score ≥60; (c) with expected survival of more than 3 months; (d) with no history of smoking; (e) with no previous underlying lung diseases such as bronchiectasis, bronchial asthma, or COPD; (f) without neoadjuvant chemotherapy; (g) with no previous treatment with neoadjuvant chemotherapy; (h) with no previous treatment with neoadjuvant chemotherapy; (i) with no previous treatment with bronchodilatation, bronchial asthma, or COPD; (j) with no previous treatment with neoadjuvant chemotherapy. (f) No neoadjuvant chemotherapy; (g) No history of other systemic malignancies; (h) Sufficient fresh tumor tissue specimens are available.
2. Participants are willing to participate in this study and comply with the study plan;
3. Participants or legally authorized representatives were able to provide written informed consent approved by the ethical review board managing the site.

Exclusion Criteria:

1. the presence of malignant tumors or metastatic foci in other parts of the body;
2. the combination of other organic diseases;
3. psychiatric disorders or communication disorders;
4. lung infections, systemic hematologic diseases, immune system diseases;
5. bronchodilatation, bronchial asthma, or chronic obstructive pulmonary disease and other underlying lung diseases;
6. within the past month, there are antibiotics, immunosuppressive drugs, hormones, probiotics, as well as any those who have taken antibiotics, immunosuppressants, hormones, probiotics, and any form of traditional Chinese medicine or proprietary Chinese medicine within the past month;
7. Those who have a history of smoking;
8. Those who have a history of occupational or environmental exposure to dust, mines, or asbestos.